Clinical Toxicology FAQ Reference

Bottom Line Up Front

LC-MS/MS cutoffs: Morphine & Codeine = 50 ng/mL (urine), 1 ng/mL (oral fluid). Any result below these thresholds is clinically and legally Negative. Results are truncated (not rounded): 19.9 becomes 19. The 1% Rule requires the parent compound to be at or above 50 ng/mL before it can be applied to explain secondary opioids.

🧪Specimen Validity & Adulteration

Creatinine (mg/dL)	Interpretation
< 2.0	Physiologically Impossible: not human urine
2.0 – 5.0	Highly Improbable: suggests direct water addition
5.0 – 20.0	Dilute: excessive fluid intake or water addition
2.0 – 20.0 with SG > 1.020	Probable Non-Urine: possible substitution (e.g., juice)
> 20.0	Normal range

Diuretics can also lower creatinine. A low creatinine paired with a normal specific gravity may indicate diuretic use rather than tampering. Interpret creatinine and SG together.

Normal range: 1.002 – 1.020.

SG Value	Interpretation
< 1.003	Dilute / Tampered
1.003 – 1.020	Normal
> 1.020 (with Cr 2–20)	Suspicious: possible non-urine substitution

Decreased SG may also indicate renal failure, glomerulonephritis, pyelonephritis, or diabetes insipidus.

pH Range	Interpretation
4.5 – 8.0	Normal physiological range
Up to 9.5	Clinical acceptance limit
< 4.5 or > 8.0 (SAMHSA forensic limit: 9.1)	Tampered

Clinical labs accept pH up to 9.5 to account for bacterial urea hydrolysis during transport; bacteria degrade urea into ammonia, raising pH. Pain medications remain stable in urine up to pH 9.5. SAMHSA forensic cutoff is 9.1; clinical standard is 9.5.

Bleach (sodium hypochlorite): oxidizing agent; degrades drug metabolites; detected via oxidant screen and abnormal odor
Vinegar / ammonia: shifts pH to extremes; detected by pH testing
Detergents / soaps: increase viscosity; cause foamy or scented urine
Commercial products (Urine Luck, CleanX): interfere with immunoassays
Powdered or synthetic urine: abnormal SG/creatinine pairing, often gelatinous texture

High viscosity alone (sticky, gelatinous, or foamy urine) is a red flag for adulteration. Reject and request a new specimen.

Yes. A dilute specimen can still contain drug metabolites at detectable levels. Quantitative results in dilute specimens should be interpreted cautiously; creatinine-normalized values help contextualize the finding.

SVT evaluates four markers: creatinine, specific gravity, oxidant activity, and pH. Each is reported Normal or Abnormal against established reference ranges. Abnormal results have multiple causes: excessive hydration, medical conditions, medications, and tampering. No single marker confirms tampering on its own.

Marker	Normal Range	What Can Cause an Abnormal Result
Creatinine	> 20 mg/dL	Excessive fluid intake, diuretics, water addition, or renal disease. Below 2 mg/dL is not physiologically possible (not human urine).
Specific Gravity	1.003 to 1.035	Low with low creatinine: dilution or water addition. Discordant high SG with low creatinine: possible salt addition or substitution.
Oxidant Activity	< 200 mcg/mL	Adulterants (nitrites, PCC, bleach, H2O2). Benign causes: UTI, dietary nitrites, blood. Colorimetric interference from phenazopyridine (Pyridium) or rifampin: orange-red urine absorbs at assay wavelengths, producing false or elevated oxidant readings.
pH	4.5 to 9.5	Acidic adulterants push below 4.5. Alkaline adulterants push above 9.5. pH can drift to 9.0 to 9.5 from storage or transport delay alone.

Dilution vs. Substitution Pattern:

Creatinine (mg/dL)	Specific Gravity	Interpretation
5.0 to < 20	< 1.003	Dilute: over-hydration or water added
2.0 to < 5.0	< 1.003	Highly improbable; probable water addition
>= 2.0 and < 20	> 1.020	Discordant: probably not urine; possible salt addition
< 2.0	Any	Not physiologically possible: specimen is not human urine

Medications Causing Colorimetric Interference (Oxidant Assay):

Medication	Urine Color	Implication
Phenazopyridine (Pyridium, Azo)	Bright orange to orange-red	High risk of false/elevated oxidant result; not adulteration
Rifampin (Rifadin)	Orange-red	Colorimetric interference at therapeutic doses (TB, MAC regimens)
Riboflavin (vitamin B2)	Bright yellow	Rarely clinically significant for validity testing
Nitrofurantoin (Macrobid)	Dark yellow to brown	Low clinical significance for oxidant testing

* Reference ranges reflect clinical laboratory thresholds used for patient care settings. See companion FAQ for federal workplace testing cutoffs.

One abnormal validity marker is not proof of tampering. Read all four together. For an elevated oxidant, always ask about phenazopyridine or rifampin before concluding adulteration.

[Gather all four validity marker results before responding if possible.]

"Let me walk through each marker and then interpret the pattern as a whole."

[Start with creatinine and SG:]

"If both are low, that is a dilute pattern from over-hydration or water addition. If creatinine is below 2 mg/dL or does not match the SG, the specimen may not be human urine."

[If oxidant is flagged:]

"Near 200 mcg/mL can reflect a UTI, dietary sources, or blood. At or above 500 mcg/mL is more consistent with an adulterant. Is the patient on phenazopyridine or rifampin? Both cause orange-red urine that interferes with the colorimetric oxidant assay."

[If pH is flagged:]

"pH can drift to 9.0 or higher from storage or transport issues alone. What was the collection temperature and how quickly was it processed?"

[Closing:]

"Read these markers together. One abnormal marker without a supporting pattern is not a basis for a tampering conclusion. If discordant, recommend observed re-collection."

Federal workplace testing (DOT, HHS-mandated programs) uses codified cutoffs that differ from clinical laboratory reference ranges. A clinically abnormal marker is not automatically adulterated or substituted under federal rules.

Classification	Marker(s)	Federal Cutoff (HHS/SAMHSA)
Substituted	Creatinine + SG	Creatinine < 2 mg/dL AND SG < 1.0010 or >= 1.0200 (both required)
Dilute	Creatinine + SG	Creatinine >= 2 to < 20 mg/dL AND SG > 1.0010 to < 1.0030
Adulterated	pH	< 4.0 or >= 11.0
Adulterated	Nitrite	>= 500 mcg/mL
Adulterated	Chromium (VI)	>= 50 mcg/mL
Adulterated	Oxidant (halogen, glutaraldehyde, pyridine, surfactant)	Present at or above confirmatory test LOQ
Invalid	pH or nitrite (intermediate)	pH 4.0 to < 4.5 or 9.0 to < 11.0; nitrite >= 200 to < 500 mcg/mL

Key differences from clinical ranges: Federal nitrite adulteration threshold is >= 500 mcg/mL (clinical labs may flag at >= 200 mcg/mL). A nitrite of 250 mcg/mL is clinically abnormal but federally invalid, not adulterated. Federal pH adulteration threshold is < 4.0 or >= 11.0 (clinical labs may flag outside 4.5 to 9.5). These are not interchangeable.

* Per SAMHSA MRO Guidance Manual and 49 CFR Part 40. Applies to DOT-regulated and other federally mandated testing programs only.

The most common confusion on MRO calls: applying federal thresholds to a clinical result. Always confirm whether the program is federally regulated before using federal classification criteria.

[MRO or drug court coordinator asks whether a result meets federal adulterated/substituted criteria.]

"First, is this a DOT-regulated test or another federally mandated program, or is it a clinical test?"

[If federal:]

"The clinical laboratory may report a marker as abnormal based on its reference ranges, but that does not automatically meet the federal threshold. Let me walk through the specific value and which federal classification, if any, applies."

[If clinical:]

"This is a clinical test, so the federal forensic cutoffs do not directly apply. We interpret against the laboratory's reference ranges and the overall validity pattern."

Absolute urine drug concentrations fluctuate with hydration, making them unreliable for serial monitoring. Creatinine normalization corrects for this by dividing the drug concentration by the creatinine concentration, expressing the result as ng/mg creatinine.

Formula (creatinine in mg/dL): Drug (ng/mL) ÷ Creatinine (mg/dL) × 100 = ng/mg creatinine

The specimen ratio (later normalized value ÷ earlier normalized value) is compared against one of two evidence-based thresholds (Huestis and Cone 1998; Manno et al. 2001):

Threshold	Accuracy	Sensitivity	FP Rate	FN Rate	Setting
≥ 0.5 (clinical)	85.4%	80.1%	5.6%	7.4%	Treatment programs; non-punitive monitoring
≥ 1.5 (forensic)	74.2%	33.4%	0.1%	24.0%	Legal proceedings; probation; child custody

Required conditions: Same laboratory and assay method; specimens collected ≥ 24 hours apart; creatinine ≥ 20 mg/dL in each. Best validated for cannabis (THC-COOH). Normalization is invalid on dilute specimens.

The 1.5 forensic threshold misses approximately 24% of new-use events. A ratio below 1.5 does not rule out new use. For treatment programs, 0.5 provides the highest overall accuracy. Do not compare results from different laboratories: the normalization baseline resets at every lab transition. (TP-SV-V03)

💊Opioids & MAT (Buprenorphine, Methadone, Opioids)

Analyte	EIA Cutoff	LC-MS/MS Urine	LC-MS/MS Oral Fluid	Detection Window
Codeine	300 ng/mL	50 ng/mL	1 ng/mL	1–2 days
Morphine	300 ng/mL	50 ng/mL	1 ng/mL	1–2 days (IR); 2–3 (ER)

Opioid Process Impurities: prescription opioids contain unavoidable manufacturing byproducts that are themselves opioids. At high doses, these impurities can be detected at low levels, raising concern about additional drug use. They are not metabolites. This concept is informally called the "1% Rule" (named because impurities are generally present at less than 1% of the parent drug concentration). The rule has one hard requirement: it cannot be applied if the parent compound is not confirmed at or above the laboratory's cutoff (typically 50 ng/mL). Without a confirmed parent, the secondary opioid must be evaluated as independent ingestion.

Prescribed Drug	Potential Impurity	Allowable %	Typically Observed %
Codeine	Morphine	0.15%	0.01–0.1%
Morphine	Codeine	0.5%	0.01–0.05%
Hydrocodone	Codeine	0.15%	0–0.1%
Hydromorphone	Morphine, Hydrocodone	0.15%, 0.1%	0–0.025%
Oxycodone	Hydrocodone	1.0%	0.02–0.12%
Oxymorphone	Oxycodone, Hydromorphone	0.5%, 0.15%	0.05–0.4%, 0.03–0.1%

* Cutoff values reflect this laboratory's thresholds. Other laboratories may use different cutoffs.

Critical Distinction: Impurity vs. Metabolite
Hydrocodone (after codeine) and hydromorphone (after morphine) are actually minor metabolites at approximately 5% of the parent drug concentration, not process impurities. This is commonly misattributed to impurities. If hydromorphone or hydrocodone appear at roughly 5% of their parent, that is metabolic, not impurity-driven.

Interpretation Criteria: a process impurity is more likely when all three conditions are present:

The secondary opioid is not a prescribed medication
Its urine concentration is low (generally below 100 ng/mL)
The prescribed parent opioid is present at a high concentration (generally above 50,000 ng/mL)

It is never possible to definitively rule out intentional use, but under these conditions impurities should be considered in the differential.

Limitations

No quantity thresholds or ratios can absolutely determine the source of an opioid
Impurity percent varies between lots and formulations; impurities are not always detected even at elevated parent concentrations
Interpretation must include clinical observation and professional judgment

Process impurities should be a diagnosis of exclusion, not a default explanation. All three criteria must be present and the full clinical picture considered. Hydrocodone/hydromorphone after codeine/morphine are more likely metabolites than impurities. Check the ratio against the parent before attributing to manufacturing.

Codeine is metabolized to morphine via CYP2D6 (approximately 5–10% O-demethylation). A morphine result in a codeine-prescribed patient is expected and does not indicate separate morphine ingestion, provided the morphine concentration is proportionate and codeine is confirmed at or above 50 ng/mL.

Possibly not. Hydrocodone is present as a manufacturing process impurity in oxycodone at up to 1% of the oxycodone concentration. If oxycodone is confirmed at or above 50 ng/mL and hydrocodone is proportionally low (less than 1% of the oxycodone value), this is consistent with the 1% Rule and does not necessarily indicate independent hydrocodone ingestion.

Heroin is rapidly deacetylated to 6-acetylmorphine (6-AM) within minutes of administration, then further to morphine. Heroin itself is rarely detected in urine.

6-AM is the unique marker for heroin use, most likely detectable within the first 24 hours. After that window, only morphine remains, which is non-specific.

If 6-AM is detected, this is definitive evidence of heroin use. Morphine alone (without 6-AM) cannot distinguish between morphine prescription, codeine metabolism, and heroin use after the 6-AM window has closed.

When buprenorphine is very high (greater than 5,000 ng/mL) with no or minimal norbuprenorphine, this strongly suggests specimen spiking: direct addition of buprenorphine to the sample rather than systemic ingestion and metabolism. Genuine physiologic use produces norbuprenorphine as the primary urinary metabolite.

The buprenorphine-to-norbuprenorphine ratio is a key diversion indicator. Absence of norbuprenorphine with a high parent drug is a red flag for specimen adulteration.

Immunoassays underrespond to the glucuronide-conjugated form of norbuprenorphine that predominates in urine, while LC-MS/MS measures total (free plus conjugated after hydrolysis) more accurately. Immunoassay values may be significantly lower. The LC-MS/MS result is the authoritative value.

In urine: Methadone without EDDP is suspicious and may indicate specimen adulteration or direct powder addition. However, very low EDDP can occur physiologically.

In oral fluid: This is within expected range. In a study of 84,148 oral fluid specimens, 62.2% of methadone-positive results had no detectable EDDP. This is biologically normal in oral fluid and should not be interpreted as deception.

Methadone without EDDP in oral fluid is common and expected. Do not use this finding alone to question a patient's adherence in oral fluid testing.

Not necessarily. A negative oral fluid result in a patient receiving long-acting injectable buprenorphine does not indicate non-adherence. Detection in oral fluid depends on passive diffusion of free drug from plasma into saliva: severely limited by buprenorphine's ~96% protein binding and the absence of direct oral cavity exposure.

Product	Route	Approx OF Positivity
Suboxone (sublingual)	Direct oral exposure	~86%
Sublocade	SubQ depot injection	~47%
Brixadi	SubQ depot injection	Comparable to or lower than Sublocade

For in-office-administered injectables, adherence is confirmed by the administration record: not drug testing. If confirmation is clinically needed, urine is the preferred matrix. Never use a negative oral fluid result alone to question adherence in a depot buprenorphine patient.

Medication	Formulations	Brand Names	Testing Notes
Buprenorphine	SL tablets, SL films, ER injection, implant	Subutex, Suboxone, Sublocade, Brixadi, Belbuca, Zubsolv	Buprenorphine + norbuprenorphine detected; may cause weak opiate EIA cross-reactivity
Methadone	Oral solution, tablets, dispersible tablets	Methadose	Requires specific methadone assay; long half-life
Naltrexone	Oral tablets, ER monthly injection	Vivitrol, Revia	Not routinely detected on standard UDT panels
Naloxone	Nasal spray, IV/IM	Narcan, Kloxxado	May appear on some panels; structurally similar to morphine on EIA

Crushing an ER tablet causes dose dumping: the full dose absorbs rapidly as if immediate-release (IR). For example, crushing ER alprazolam (half-life ~16 hrs) converts it to behave like IR alprazolam (half-life ~11 hrs). The urine profile shows a more rapid rise and fall in metabolite concentrations compared to the expected ER pattern.

The LC-MS/MS result is correct. Buprenorphine can cross-react with some immunoassay opiate panels at high concentrations due to structural similarity to other opioids. The immunoassay is a screening test only: LC-MS/MS is the authoritative result.

In a patient on chronic, high-dose oxycodone therapy, oxymorphone is expected to be present in urine as a secondary metabolite at steady state. Its absence is clinically significant and raises concern for non-compliance: the patient may not be taking the medication as prescribed, or may be taking it only immediately before collection.

Metabolic pathway: Oxycodone → Noroxycodone (CYP3A4, major) and Oxymorphone (CYP2D6, minor) → Noroxymorphone (terminal). At steady state, all three downstream metabolites should be detectable.

Pattern	Interpretation
Oxycodone + noroxycodone + oxymorphone all present	Consistent with regular as-prescribed use at steady state
Oxycodone + noroxycodone present; oxymorphone absent	Raises concern for acute single dose prior to collection or non-compliance with regular dosing
Oxycodone only; no metabolites	Highly suspicious for specimen spiking or very recent isolated ingestion
All analytes absent	Non-compliance: medication not being taken

Caveat: Within approximately 4 to 5 hours of a single acute dose, oxymorphone may not yet appear in urine. Timing of the last dose relative to specimen collection must be considered before concluding non-compliance.

The "taking it only before the visit" pattern is a recognized non-compliance scenario. A patient on twice-daily long-acting oxycodone who shows oxycodone and noroxycodone but absent oxymorphone may be hoarding or diverting and ingesting a dose acutely prior to the visit. For twice-daily long-acting formulations, oxymorphone should be continuously present at steady state. Document the full metabolite pattern alongside the prescribed dose and frequency. (TP-OPI-V01)

In a patient taking sublingual buprenorphine as prescribed, norbuprenorphine should be present. At steady state, the norbuprenorphine-to-buprenorphine (norBUP:BUP) ratio typically exceeds 1.0. A ratio below 0.02 (< 2%) strongly suggests specimen spiking: adding medication directly to the urine collection cup rather than ingesting it.

Standard validity markers (creatinine, specific gravity, pH, temperature) remain normal in a spiked specimen and will not detect diversion. The norBUP:BUP ratio is the discriminating marker.

norBUP:BUP Ratio	Interpretation	Next Step
> 1.0	Expected with ingested medication at steady state	Document as consistent with prescribed use
0.02 to 1.0	Possible underdosing, recent initiation, or altered metabolism	Correlate with dosing history and collection timing
< 0.02 (or norbuprenorphine absent)	Spiking cannot be excluded	Request LCMS confirmation; consider observed recollection

Norbuprenorphine is a CYP3A4-mediated hepatic metabolite; it can only appear in urine following in vivo metabolism. A specimen with high buprenorphine but absent norbuprenorphine was not ingested. Do not apply these thresholds to patients with a Sublocade or Brixadi history. (TP-BUP-V01)

Yes. Sublocade (subcutaneous extended-release buprenorphine) forms a solid depot at the injection site. The manufacturer-labeled half-life is 43 to 60 days per injection. After the last injection, buprenorphine has been detected in plasma and urine for 12 months or longer. This is expected depot pharmacokinetics, not ongoing illicit use.

Product	Half-Life	Expected Positive Duration After Last Dose
Suboxone (sublingual)	24–42 hours	3–7 days
Sublocade (monthly SubQ)	43–60 days	Up to 12 months or longer
Brixadi (weekly/monthly SubQ)	Formulation-dependent	Weeks to months

The norBUP:BUP spiking thresholds (TP-BUP-V01) apply to sublingual buprenorphine only. Depot pharmacokinetics produce different urine concentration patterns. Document injection history alongside UDS results. If LCMS concentration appears inconsistent with expected depot elimination, consider whether concurrent sublingual buprenorphine is being used. (TP-BUP-V02)

This is a well-documented immunoassay false positive. Risperidone, paliperidone, and ziprasidone share a structural moiety with fentanyl that cross-reacts with the antibody used in fentanyl immunoassays, producing a positive screen in the absence of actual fentanyl. LCMS identifies drugs by molecular mass and chemical structure: a negative LCMS definitively excludes fentanyl.

No clinical action for fentanyl use should be taken on a screen-only positive when LCMS confirmation is negative.

Antipsychotic	Cross-Reactivity	Notes
Risperidone	Well-documented	Oral and depot (Risperdal Consta) formulations
Paliperidone (9-OH-risperidone)	Well-documented	Also Invega Sustenna, Invega Trinza
Ziprasidone (Geodon)	Reported	Structural similarity to fentanyl

Long-acting injectable antipsychotics (Risperdal Consta, Invega Sustenna, Invega Trinza) maintain sustained concentrations over weeks to months, producing false-positive fentanyl screens at every collection. Establish this expectation in the chart at program entry and make LCMS confirmation the standing order for all fentanyl screens in antipsychotic-treated patients. (TP-FENT-V02)

⚡Stimulants (Methamphetamine, Amphetamine, Cocaine)

No. Three scenarios apply: (1) Adderall and Vyvanse do not produce methamphetamine on LC-MS/MS; amphetamine and methamphetamine are separate analytes. (2) Chiral analysis differentiates illicit methamphetamine from OTC l-isomer sources. (3) Methamphetamine has been documented as a manufacturing impurity in some pharmaceutical amphetamine products, producing low-level near-cutoff mAMP in patients on high-dose prescribed AMP.

Chiral Analysis (d/l isomer testing):

% d-isomer (mAMP)	Interpretation	Notes
20% or more d-mAMP	Positive for d-isomer	Illicit mAMP, Desoxyn (Rx), or manufacturing impurity from AMP product. d-Isomer alone does NOT rule out impurity.
Less than 20% d-mAMP	Positive for l-isomer	OTC l-desoxyephedrine (generic vapor inhalers) or selegiline metabolism
Any result above 10,000 ng/mL	Strongly illicit	Effectively excludes OTC, selegiline, and manufacturing impurity

Manufacturing Impurity Criteria (only applies when high prescription AMP is also present):

Criterion	Impurity Pattern	Illicit Use Pattern
AMP result	High (prescribed; 5,000+ ng/mL)	Absent or inconsistent with prescription
mAMP result	Low; near or slightly above cutoff	Moderate to high; often 1,000+ ng/mL
mAMP:AMP ratio	Below 0.5%	Typically well above 0.5%
d/l isomeric correlation	mAMP and AMP d/l ratios closely match	May diverge
Other illicits	Absent	Often co-detected

Only 2.1% of amphetamine-prescribed patients without a SUD diagnosis test positive for both AMP and mAMP (Millennium Health, N=38,452, 2022-2024). Evaluate the mAMP:AMP ratio before concluding illicit use. Below 0.5% with matching d/l isomeric profiles supports manufacturing impurity. See also: TP-MAMP-V02.

No. Methylphenidate (Ritalin, Concerta) does not produce false positives for methamphetamine or amphetamine on LC-MS/MS. LC-MS/MS is analyte-specific: methylphenidate metabolizes to ritalinic acid, not to AMP or mAMP. Immunoassay cross-reactivity is very low with modern assays; confirm any unexpected positive by LC-MS/MS.

Test Type	Methylphenidate Cross-Reactivity?	Clinical Action
POC / EMIT immunoassay	Very low with modern assays	Confirm by LC-MS/MS if unexpected positive obtained
LC-MS/MS (confirmatory)	None. Analyte-specific.	Confirmed positive is not a methylphenidate artifact. Assess for separate drug use. If AMP also present, see TP-MAMP-V01.

Methylphenidate metabolizes to ritalinic acid, not to amphetamine. A confirmed LC-MS/MS positive for AMP or mAMP in a patient prescribed only methylphenidate indicates separate drug use.

Yes. Topical cocaine (used in ENT/dental procedures) is systemically absorbed and produces a positive urine benzoylecgonine result. The patient's clinical history should be considered. Coca leaf teas can also produce positive results.

Yes. In approximately 31% of oral fluid cases, benzoylecgonine is absent despite a positive cocaine result, due to pharmacogenomic variance in esterase activity in saliva.

Absence of benzoylecgonine in oral fluid does NOT invalidate a positive cocaine result. The parent drug is the primary analyte in oral fluid testing. This is biologically normal, not a lab error.

Current evidence suggests semen-mediated cocaine transfer is highly unlikely to produce a positive urine result at standard clinical cutoffs (50–100 ng/mL BE). Based on the available data, this pathway is not expected to generate detectable benzoylecgonine in a partner's urine under typical conditions. However, the published literature is limited and should be applied with clinical judgment.

The only primary data comes from Cone et al. (1996), a letter-level report measuring cocaine in seminal plasma of drug users. Peak seminal plasma cocaine was approximately 10 mcg/g in chronic heavy users. A typical ejaculate is 2–3 grams, yielding an estimated maximum of 20–30 mcg cocaine per encounter. The authors extrapolated approximately 10,000 precisely timed sexual encounters before a non-using partner might approach a positive drug test. No published study has documented a confirmed positive attributable to this pathway.

A separate scenario is direct urine specimen contamination (if semen is deposited shortly before voiding and collection is not done cleanly) shortly before voiding and collection is not done cleanly. If suspected, prostate-specific antigen (PSA) testing can serve as a seminal marker.

Parameter	Value / Notes
Peak cocaine in seminal plasma	~10 mcg/g (Cone 1996, letter-level; limited sample)
Estimated cocaine per ejaculate	~20–30 mcg maximum
BE needed for 50 ng/mL positive (300 mL void)	~15 mcg minimum, before distribution and clearance
Encounters to approach a positive (est.)	~10,000 (author extrapolation, not empirically validated)
Published confirmed positives via semen	None identified in peer-reviewed literature to date

* Cutoff values reflect this laboratory's thresholds. Other laboratories may use different cutoffs. Confirm with the reporting lab before making clinical decisions.

When evaluating this claim, consider the reported BE concentration. Higher concentrations make the explanation progressively less plausible. The mass-balance calculation alone does not support this mechanism at standard cutoffs under typical conditions. Present this as current evidence, not settled science.

"Thank you for calling. I understand you have a question about a positive cocaine result in a patient claiming exposure through her partner."

[Listen for the reported concentration and collection circumstances before responding.]

"Based on the available evidence, semen-mediated cocaine transfer is not expected to produce a positive urine result at standard cutoffs. The cocaine concentrations documented in semen are too low, and the volume per encounter too small, to generate detectable benzoylecgonine in a partner's urine under typical conditions."

"That said, the published literature in this area is limited, so I would not present this as completely settled. No published study has documented a confirmed positive from this pathway."

[If caller asks about concentration:] "What was the reported BE level? Higher concentrations make this explanation progressively less plausible."

[If contamination is raised:] "If there is concern about direct specimen contamination rather than systemic absorption, the specimen can be tested for PSA as a seminal marker."

"Is there anything specific about the clinical picture I can help you think through?"

Yes. When cocaine is applied directly to the penis or perigenital mucosa, systemic absorption is pharmacologically expected. Cocaine is a topical anesthetic because it absorbs through mucosal tissue: the same mechanism used in ENT nasal procedures, ophthalmic Horner syndrome testing, and TAC wound anesthesia (tetracaine-adrenaline-cocaine). The glans penis and urethral meatus are highly vascularized mucosal surfaces with minimal keratinization, comparable to nasal or oral mucosa. This is a mechanistically distinct and more clinically credible scenario than semen-mediated transfer (see TP-COC-V01 above).

Key distinction from semen-mediated transfer: The semen transfer scenario involves cocaine metabolites at extremely low concentrations (approximately 20-30 mcg per ejaculate) that are insufficient to produce a positive at standard cutoffs. Topical application involves the parent cocaine drug in direct mucosal contact, the same route confirmed to produce positive urine drug screens in medical literature.

Scenario	Expected UDS	Basis
Direct applicator (cocaine applied to own penis)	Likely positive	Direct mucosal absorption; equivalent to TAC or nasal topical use; recreational dose may exceed medical doses substantially
Sexual partner (vaginal contact with cocaine-coated penis)	Plausible positive; concentration-dependent	Vaginal mucosa is an established absorption route (pharmaceutical drug delivery); no direct study exists, extrapolated from mucosal absorption pharmacology
Intact skin contact only (no mucosal surface)	Negative expected	Kavanagh 1992: passive aerosol and cutaneous exposure in medical staff produced no positive urine results

Medical literature supporting mucosal absorption: Altieri et al. (1990) found 78% positive by EMIT and 83% by GC-MS after a single TAC topical anesthetic application, with results persisting 36-48 hours (PMID 2184707). Fitzmaurice et al. (1990) detected benzoylecgonine at 40 to >600 ng/mL in plasma within 20-40 minutes of TAC application in pediatric patients (PMID 2331095). The FDA nasal cocaine label explicitly warns of positive urine drug screens after clinical use.

Detection window: Benzoylecgonine (standard cocaine target) detectable approximately 24-72 hours after a single mucosal exposure. Cutoffs vary by test type and laboratory: POC cups commonly 300 ng/mL; clinical EIA/immunoassay typically 50-300 ng/mL (lab-dependent); LC-MS/MS confirmatory typically 5-150 ng/mL (lab-dependent); federal/forensic (DOT/SAMHSA) 150 ng/mL immunoassay, 100 ng/mL confirmatory. Confirm specific cutoffs with your laboratory before interpreting results.

Consultant's Pearl (TP-COC-V02): Cocaine works as a topical anesthetic precisely because it absorbs through mucous membranes. For the direct applicator, a positive UDS is pharmacologically expected, not implausible. For the partner, the exposure is plausible in principle via vaginal mucosal contact with cocaine residue, but not confirmed by direct published evidence. Both scenarios are more credible than the semen-transfer explanation (TP-COC-V01). Document carefully: who applied the cocaine, when, and in what quantity if known.

[Clarify who is positive: the person who applied cocaine or their partner? Ask this before proceeding.]

"Before I address this, I want to make sure I understand the scenario. Which person tested positive: the one who applied the cocaine to their genitals, or their sexual partner?"

[If positive is in the direct cocaine applier:]

"In that case, a positive urine drug screen is pharmacologically expected. Cocaine absorbs through mucosal tissue. This is the same reason it is used as a topical anesthetic in ENT and wound care. Medical studies using topical cocaine wound anesthetics found 78 to 83% of patients test positive for benzoylecgonine after a single application, with results persisting up to 36 to 48 hours. The glans penis is mucosal tissue with similar absorption characteristics. This explanation is pharmacologically credible and should be documented."

[If positive is in the sexual partner:]

"That is a different scenario from the cocaine-in-semen question. Here we are talking about cocaine residue on the penis coming into direct contact with vaginal mucosa during penetration. The vaginal mucosa is a well-documented absorption route: it is used for pharmaceutical drug delivery. There is no published study specifically on this scenario, but the pharmacological basis is sound. The absorbed dose depends on residual cocaine concentration and contact duration. I would characterize this as plausible in principle but not confirmed by direct published data."

[If asked whether to accept or document the explanation:]

"For the direct applicator, this is a pharmacologically credible explanation that should be documented in the record. For the partner, document it as a reported exposure that is plausible but without direct supporting evidence. Either way, this is a substantially more credible claim than semen-mediated transfer."

No, not at standard confirmatory cutoffs. Controlled passive inhalation studies using a methamphetamine structural analog found maximum urinary concentrations of approximately 13.4 ng/mL after passive inhalation, roughly 1/60th of the level seen with active use (~800 ng/mL) and far below the 250 ng/mL SAMHSA confirmatory cutoff (Morinaka et al., 2023). Incidental skin contact with contaminated surfaces does not produce detectable urinary levels under normal conditions. Drug testing cutoffs are specifically designed to exclude environmental exposure levels.

The only scenario warranting additional evaluation is a near-cutoff result in a highly concentrated specimen (markedly elevated creatinine), where dehydration may have artificially elevated the analyte level. Even with extreme urine concentration, passive exposure cannot bridge the gap between a maximum of ~13 ng/mL and a 250 ng/mL confirmatory cutoff.

Exposure Scenario	Max Urinary Conc.	SAMHSA Cutoff	Sufficient?
Active inhalation (direct use)	~800 ng/mL (Morinaka 2023)	250 ng/mL	Yes
Passive inhalation (same room as user)	Max 13.4 ng/mL (approx. 1/60th of active)	250 ng/mL	No
Incidental skin contact	Below detection under normal conditions	250 ng/mL	No

Consultant's Pearl (TP-MAMP-V03): The passive exposure defense for methamphetamine has no toxicological support at standard confirmatory cutoffs. The maximum concentration from passive inhalation (13.4 ng/mL) is approximately 19-fold below the SAMHSA threshold (250 ng/mL). If the result is near the cutoff in a concentrated specimen, apply creatinine normalization and request a repeat. Outside that narrow window, a confirmed result reflects active use regardless of cohabitation with a user, presence in a vehicle, or handling of paraphernalia.

"Let me look at the quantitative methamphetamine level and the specimen creatinine. What were those numbers?"

[If result substantially above 250 ng/mL or creatinine is normal:]

"Based on controlled passive inhalation research, the maximum urinary methamphetamine concentration from passive exposure is approximately 13.4 ng/mL. The confirmatory cutoff is 250 ng/mL. That is approximately a 19-fold difference. Passive exposure does not explain a confirmed positive at standard cutoffs."

[If result near cutoff with markedly elevated creatinine:]

"The specimen is concentrated, which can artificially elevate all analyte levels. I would apply creatinine normalization and recommend a repeat specimen under standard hydration conditions. However, even accounting for concentration, passive exposure cannot approach 250 ng/mL."

[If asked about skin contact or handling paraphernalia:]

"Incidental contact with surfaces or objects exposed to methamphetamine does not produce detectable urinary levels under ordinary circumstances. Confirmatory cutoffs are specifically set to exclude environmental exposure."

🌿THC / Cannabis

Use Pattern	Approximate Detection Window
Single use	3–4 days
Moderate use (few times/week)	5–7 days
Daily use	10–15 days
Chronic heavy use	Up to 30+ days

THC-COOH is fat-soluble and accumulates in adipose tissue, causing extended detection windows in chronic users.

A decreasing THC-COOH concentration over serial specimens is consistent with abstinence. An increasing level suggests new use.

Very unlikely. Even under extreme conditions (unventilated room, prolonged heavy exposure), passive inhalation produces THC-COOH levels rarely exceeding 30 ng/mL: well below the standard 50 ng/mL cutoff.

Passive inhalation is not a defensible explanation for a confirmed positive THC result at or above the 50 ng/mL cutoff under real-world conditions.

Marinol (dronabinol, synthetic THC): Yes: dronabinol is metabolized to THC-COOH and produces a positive result identical to cannabis use.

Hemp-derived CBD products: Regulated products must contain less than 0.3% delta-9-THC, but concentrated or impure products may produce a positive test, especially with heavy use.

Delta-8, Delta-9, and Delta-10 THC are structural isomers: same molecular formula, but the double bond sits at a different position in the THC ring, changing CB1 affinity, potency, and psychoactive profile.

Isomer	Potency vs Delta-9	Parent Half-Life	Clinical Profile
Delta-9-THC	100% (reference)	4–6 hrs	Classic intoxication; euphoria, impaired coordination; highest impairment risk
Delta-8-THC	~50–70%	4–8 hrs	Milder, calmer; less anxiety/paranoia; still impairing; widely sold in gas stations/vape shops
Delta-10-THC	~20–40%	4–8 hrs	More energizing/uplifting; lighter euphoria; "functional high"

THC-COOH half-life is 20–60 hours for all isomers. Chronic use of any isomer produces extended detection (days to weeks).

All delta isomers metabolize to the same urinary metabolite: THC-COOH. Routine LC-MS/MS confirmation cannot differentiate which isomer was used. A confirmed positive is a positive, regardless of the source isomer.

No. Standard drug testing cannot assign a THC-COOH positive to a specific isomer source.

Many retail Delta-8/Delta-10 products contain measurable Delta-9-THC due to poor manufacturing controls
Chronic Delta-8 or Delta-10 use produces prolonged THC-COOH positivity identical to cannabis use
Drug courts and monitoring programs typically treat all delta isomers identically

Suggested monitoring program language: "Use of intoxicating cannabinoids (including Delta-8-THC, Delta-10-THC, HHC, and related products) is prohibited. Routine testing cannot differentiate product source. A confirmed cannabinoid positive stands regardless of claimed retail cannabinoid use."

HHC is a hydrogenated cannabinoid. Unlike delta isomers (positional), HHC's "isomers" are stereoisomers: 9R-HHC (more CB1-active, more psychoactive) and 9S-HHC (less active). Commercial HHC products are a variable mixture of both.

Feature	Delta-9-THC	HHC (retail products)
Standard urine target	THC-COOH: detected on all panels	HHC-COOH-type metabolites: not included on most standard panels
LC-MS/MS confirmation	Confirmed as THC-COOH	Often missed or non-specifically reported; requires targeted HHC method

A claim of "HHC only" does not explain a positive THC-COOH result. Standard confirmations detect THC-COOH, not HHC metabolites. Without a lab that specifically tests for HHC, the distinction cannot be made.

11-hydroxy-THC (11-OH-THC) is an active intermediate metabolite of THC, at least equipotent to: and often more potent than: Delta-9-THC on a mg-for-mg basis.

Oral THC (edibles, capsules) produces proportionally more 11-OH-THC than inhaled cannabis due to first-pass hepatic metabolism. This explains why oral cannabis causes stronger, longer intoxication at equivalent doses and is a common cause of unexpected overdose with edibles.

11-OH-THC is not a routine urine confirmation target: standard panels report THC-COOH only.

When a patient reports using edibles and the clinical picture seems disproportionate to the stated dose, 11-OH-THC accumulation is the pharmacological explanation: not patient exaggeration.

No. Oral fluid (OF) and urine detect different analytes with different detection windows. OF detects parent THC (delta-9-THC), which clears within hours of use. Urine detects THCCOOH (the inactive metabolite), which persists for days to weeks. A positive urine with a negative OF is the expected pattern after recent but not acute use, and is not contradictory.

Detection windows by use pattern:

Use Pattern	OF THC (parent drug)	Urine THCCOOH (metabolite)
Single use	Avg 15 h consecutive positive; last positive up to ~34 h (Niedbala 2001)	Avg 26-33 h consecutive; last positive up to 42-58 h (Niedbala 2001)
Occasional (1-3x/week)	Hours to ~24 h after last use	3-7 days
Chronic/daily use	~48 h during monitored abstinence (Lee/Huestis 2011)	Weeks; 73% below cutoff within 2 weeks (Lewis 2015); documented positive at least 24 days in heavy users (Lowe/Huestis 2009)

Can secondhand cannabis smoke cause a positive result?
Urine THCCOOH: No. This metabolite requires hepatic metabolism of absorbed THC. Ambient passive inhalation does not deliver sufficient THC to produce THCCOOH at detectable levels at standard cutoffs.
OF THC: Environmental contamination of the collection device is possible only if it is directly exposed to active cannabis smoke during collection. When specimens are collected outside the smoke environment (even 30-45 min after leaving), passive subjects test negative (Niedbala 2005). This is not a realistic risk in clinical monitoring settings.

Consultant's Pearl (TP-THC-V01): OF answers "did this person use cannabis in the last several hours?" Urine answers "has this person used cannabis in the last days to weeks?" A negative OF with a positive urine is consistent with use that occurred hours or days ago, not contradictory to it. Chronic users may remain urine-positive for weeks after the last use. When a patient challenges a positive urine with secondhand exposure, the toxicology is clear: THCCOOH in urine requires hepatic metabolism, not ambient inhalation.

"These two tests measure different things, so they do not need to agree. Oral fluid detects the active THC drug, which clears within hours. Urine detects an inactive metabolite that persists for days to weeks. A positive urine with a negative oral fluid result means the patient used cannabis more than a few hours before collection. The results are consistent with each other."

[If asked about secondhand vape or smoke causing the positive urine:]

"The metabolite detected in urine (THCCOOH) is only produced when the liver metabolizes absorbed THC. Passive inhalation of ambient cannabis smoke does not deliver enough THC to produce this metabolite at detectable concentrations in urine. Secondhand exposure does not explain a positive urine at standard cutoffs."

[If chronic user claims abstinence:]

"In daily cannabis users, THC stored in fat tissue continues to be released and metabolized during abstinence. Chronic users can remain urine-positive for two weeks or longer after their last use. A positive result during claimed abstinence is consistent with either ongoing use or documented prior heavy chronic use."

😴Benzodiazepines

Chlordiazepoxide has a complex metabolic cascade: Chlordiazepoxide → Desmethylchlordiazepoxide → Demoxepam → Nordiazepam → Oxazepam. All metabolites may appear in urine.

A patient prescribed only chlordiazepoxide (Librium) can test positive for nordiazepam and oxazepam. These are expected metabolites, not evidence of additional benzodiazepine use.

Diazepam is not directly measurable in urine at standard assay thresholds. What the test detects are its three active metabolites: nordiazepam, temazepam, and oxazepam. The textbook diazepam pattern is all three metabolites present together.

Analyte	Single Dose Detection Window	Chronic Use
Diazepam + metabolites (combined)	7–10 days	Up to 6 weeks or longer
Nordiazepam (t½ 36–200 hours)	Up to 2 weeks	Persists significantly longer
Oxazepam (t½ 5–15 hours)	3–5 days	Less accumulation

Detection windows extend significantly in older patients and those with hepatic impairment. Diazepam and nordiazepam are highly lipophilic and accumulate in adipose tissue with chronic use.

Nordiazepam in the urine does not mean diazepam. Chlordiazepoxide (Librium) and clorazepate (Tranxene) also produce nordiazepam as a metabolite. When nordiazepam appears unexpectedly, check the PDMP for all three parent compounds before drawing a conclusion. Temazepam is also a direct prescription in some programs: its presence alongside nordiazepam does not automatically indicate diazepam as the source. (TP-BZD-V01)

⚠️Emerging Substances & Novel Psychoactives (NPS)

Crystallized pyrethroid-based insecticide (wasp spray) used as an injectable drug of abuse. Created by spraying insecticide through an electrified wire screen; the crystals resemble crystal methamphetamine.

Mechanism: Pyrethroids are sodium/chloride channel modulators that suppress GABA activity, producing a methamphetamine-like "rush."

Clinical risks: IV injection can cause multiorgan failure (lungs, heart, liver, kidneys). No specific antidote; treatment is supportive.

Geographic prevalence: Reported in KY, FL, NY, OH, TN, TX, WV.

Wasp dope is NOT detected on standard drug panels. If a patient presents with methamphetamine-like symptoms but negative toxicology, wasp dope is a differential consideration in endemic areas.

Kratom (Mitragyna speciosa) contains two primary alkaloids detected by LC-MS/MS: mitragynine (the dominant alkaloid) and 7-hydroxymitragynine (7-OH). Standard immunoassay panels do not detect kratom. Specific LC-MS/MS testing reports both analytes quantitatively in ng/mL. Reference ranges have not been established for either analyte.

Parameter	Mitragynine	7-OH Mitragynine
Role in traditional kratom	Dominant alkaloid (~80-90% of alkaloid content)	Minor component (<2% of alkaloids in whole-leaf)
Mu-opioid receptor potency	Weak partial agonist; ceiling effect limits opioid-like risk	~13x morphine; ~40x mitragynine (in vitro data only)
Source of 7-OH in urine	N/A	Metabolic conversion from mitragynine AND/OR direct ingestion of concentrated 7-OH product; cannot be distinguished by urine result alone
Reference ranges established?	No	No
Regulatory status	Not federally scheduled; DEA drug of concern	FDA recommending scheduling of concentrated products under CSA (July 2025)

Product type is more clinically informative than analyte levels alone. Urine LC-MS/MS cannot distinguish traditional whole-leaf kratom use from use of a concentrated or synthetically derived 7-OH product. Ask about product form (whole-leaf powder, encapsulated supplement, extract, or 7-OH concentrate). Concentrated 7-OH products carry a risk profile comparable to conventional full mu-opioid agonists.

Product Type	Typical Finding	Clinical Risk
Whole-leaf / powder / tea	Mitragynine predominant; low 7-OH if detected	Lower risk; partial agonist ceiling; withdrawal still possible
Kratom extract / full-spectrum	Higher mitragynine; 7-OH may be elevated	Higher potency; closer to conventional opioid risk profile
Concentrated / isolated 7-OH product	7-OH disproportionately elevated relative to mitragynine	High risk: treat clinically as high-potency opioid; evaluate for co-ingestion
Product labeled as kratom (unknown)	Variable; any ratio possible	Cannot assume traditional leaf profile; obtain product details

* Potency estimates (13x morphine, 40x mitragynine) are from in vitro and animal studies. No validated human morphine-equivalent conversion exists for 7-OH mitragynine. Do not use these figures for dose conversion. Deaths associated with kratom products have nearly all involved polysubstance use or co-contaminants; a positive result should prompt evaluation for other co-ingested substances.

Consultant's Pearl (TP-KRA-V01): The clinical question isn't "how high is the 7-OH?" Reference ranges don't exist and the in vitro potency data doesn't translate to a dose-conversion equation. The better question is: what product is this patient actually using? A patient using traditional whole-leaf kratom powder has a different risk profile than one purchasing a concentrated 7-OH extract online, even if the numeric result looks similar. Lead with product type, not the number.

[Gather: product type the patient reported using, symptom picture, other substances present, MAT status.]

"Thank you for calling. I understand you have a question about a kratom result, specifically about the mitragynine and 7-OH mitragynine levels."

"Mitragynine is the main alkaloid in traditional whole-leaf kratom. It acts as a relatively weak, partial opioid agonist; it has ceiling effects that limit the opioid-like risk compared to conventional opioids. The 7-OH mitragynine is far more potent, roughly 13 times morphine in animal studies, but in traditional whole-leaf kratom it makes up a very small fraction of the alkaloid content, so the overall risk profile is lower."

"The challenge is that we cannot tell from the urine result alone whether the 7-OH is coming from metabolic conversion of mitragynine (which happens normally) or from a concentrated 7-OH product the patient ingested directly. Those products (sometimes still labeled as kratom) carry a risk profile much closer to a conventional opioid."

"Right now, the most actionable clinical step is confirming what product the patient is actually using: whole-leaf powder, a standard supplement, or an extract or concentrated product. That product history is more informative than the numeric result alone at this point."

[If asked about morphine-equivalent dose:]

"There isn't a validated human dose-conversion equation for 7-OH mitragynine yet; the potency estimates are from in vitro and animal data. Use the result for risk stratification rather than dose conversion."

"Is there anything specific about the patient's clinical picture (symptoms, co-medications, or history) that I can help you think through?"

Phenibut is a GABA-B agonist (similar to baclofen) available online as a supplement. Not detected on standard drug panels. Clinical presentation can mimic benzodiazepine or alcohol intoxication/withdrawal.

Phenibut withdrawal can be severe: similar to benzodiazepine withdrawal. Taper protocols similar to GABA-acting agents may be needed.

No. Standard labs cannot detect inhalants by urine drug testing. Inhalants are volatile compounds and must be captured via breath testing.

Nitrous oxide specifically: Half-life is approximately 5 minutes via exhalation. The standard diagnostic approach for chronic abuse is measuring B12 and homocysteine levels: nitrous oxide inactivates vitamin B12 and elevates homocysteine.

Yes. Topical ketamine (e.g., 10% cream) is systemically absorbed and will produce a positive result for both ketamine and its metabolite norketamine by LC-MS/MS (cutoff typically 50 ng/mL, creatinine-normalized).

Per ACMT and AACT joint statement (July 2017): incidental skin contact with fentanyl powder is extremely unlikely to cause toxicity or a positive drug test. Reported symptoms in emergency responders following skin contact have not been consistent with opioid poisoning.

A positive fentanyl result in a first responder claiming only incidental skin contact is not credibly explained by that exposure. Active inhalation or ingestion is the more plausible explanation for a confirmed positive.

💧Oral Fluid Testing

Standard oral fluid panels include: amphetamine, methamphetamine (MDMA and metabolite), opiates (codeine, morphine, hydrocodone, hydromorphone, 6-AM), cocaine (metabolite), THC, and PCP.

Drug	Approximate OF Detection Window
Amphetamine / Methamphetamine	1–3 days
Cocaine	1–2 days
THC (cannabis)	12–24 hours (current use indicator)
Opioids (morphine, codeine)	1–2 days; cutoff 1 ng/mL
Buprenorphine	2–3 days
Methadone	1–2 days

Oral fluid is a better indicator of recent use (hours to 1–2 days) compared to urine. THC in oral fluid is particularly useful as a same-day use indicator.

Long-acting injectable buprenorphine releases drug slowly into systemic circulation from a subcutaneous depot: with no direct oral cavity exposure. Detection in oral fluid depends on passive diffusion of free drug from plasma into saliva, severely limited by buprenorphine's ~96% protein binding.

Product	Route	OF Positivity Rate
Suboxone (sublingual)	Direct oral exposure	~86%
Sublocade	SubQ depot injection	~47%
Brixadi	SubQ depot injection	Comparable to or lower than Sublocade

For in-office-administered injectables, adherence is confirmed by the administration record. If confirmation is needed, urine is the preferred matrix. Never use a negative oral fluid result alone to question adherence in a depot buprenorphine patient.

Hand sanitizer (alcohol-based) does not significantly affect oral fluid drug results when used normally before collection. The amount of alcohol transferred to the oral cavity is insufficient to produce a positive EtG result in oral fluid.

Breath mints: Generally not a concern for drug panels. They may transiently affect pH but do not produce false positives for drugs.

No. A confirmed fentanyl-positive oral fluid result reflects systemic drug absorption, not surface contact or passive environmental exposure.

The decisive evidence is norfentanyl, the CYP3A4-mediated hepatic metabolite of fentanyl. Environmental or passive exposure (touching contaminated surfaces, proximity to fentanyl powder) does not produce systemic absorption sufficient to generate norfentanyl. When LCMS detects norfentanyl alongside fentanyl in an oral fluid specimen, systemic absorption and hepatic metabolism are confirmed.

Scenario	Fentanyl in OF	Norfentanyl in OF	Interpretation
Systemic use (any route)	Present	Present	Confirmed systemic absorption
Passive environmental contact	Trace (if any)	Absent	Not consistent with use
Pre-analytic specimen contamination	May be present	Absent	No in vivo metabolism occurred

Norfentanyl is the argument. Environmental contact with fentanyl powder does not produce hepatic CYP3A4 metabolism. If LCMS confirms norfentanyl in the oral fluid specimen, systemic absorption occurred regardless of route. Always order LCMS with individual analyte reporting (fentanyl and norfentanyl separately) before taking clinical action on any oral fluid fentanyl screen. (TP-FENT-V01)

📊Reporting, Cutoffs & Lab Standards

Results are truncated (decimal dropped), not rounded: carried over from forensic toxicology standards. Truncation ensures a patient is never rounded up to a positive at the cutoff level.

Example: cutoff is 20 ng/mL, raw result is 19.9 ng/mL. Rounding reports 20 (positive). Truncation correctly reports 19 (negative).

If a report shows 19 ng/mL for a cutoff of 20 ng/mL, the result is negative. Never assume a sub-threshold truncated result equals a positive.

Term	Definition	Clinical implication
Sensitivity	Ability to correctly identify true positives (drug present, test positive)	High sensitivity = fewer false negatives
Specificity	Ability to correctly identify true negatives (drug absent, test negative)	High specificity = fewer false positives

Immunoassay (EIA): high sensitivity, lower specificity: good for screening, prone to cross-reactivity false positives.
LC-MS/MS: high sensitivity AND specificity: the definitive confirmatory standard.

No. Results below the established LC-MS/MS cutoff are analytically Negative: they should be classified as "trace" or "sub-threshold" and are indefensible as the basis for clinical or legal action.

Example: A 15 ng/mL codeine result against a 50 ng/mL cutoff is 3.3 times below the reporting threshold. This result is clinically and legally Negative.

Sub-threshold "trace" data near the Limit of Detection (LOD) is considered analytically unreliable. Do not use these results to counsel or take action against patients.

Parameter	Forensic (SAMHSA/DOT)	Clinical
Purpose	Employment, legal, government	Patient care, monitoring
pH acceptance	Up to 9.1	Up to 9.5
Chain of custody	Required	Not always required
Reporting	MRO review required	Direct physician interpretation

Clinical labs use forensic truncation standards but may apply different cutoffs and acceptance criteria. Always verify whether a result is from a forensic-standard or clinical workflow.

🍺Alcohol Biomarkers (EtG / EtS)

Not always at low concentrations. EtG detects alcohol consumption up to 72–80 hours after last use, but incidental exposure can cause low-level positives:

Alcohol-based hand sanitizers, mouthwashes
Some foods (kombucha, very ripe fruit, certain breads)
Certain medications

Cutoff interpretation: EtG below 100 ng/mL may represent incidental exposure. EtG above 500 ng/mL is more consistent with beverage alcohol consumption.

EtG is more sensitive than EtS but also more prone to incidental exposure artifacts at low concentrations. Consider both values together and apply context: workplace vs. clinical monitoring settings may use different threshold interpretations.

An EtG-positive/EtS-negative pattern is atypical for standard beverage alcohol consumption. Both markers are expected to be present following alcohol ingestion because EtG (ethyl glucuronide) and EtS (ethyl sulfate) are formed through separate but concurrent hepatic pathways. When EtG is detected but EtS is absent, consider three possibilities:

Very remote or low-level exposure: EtS clears slightly faster than EtG and may fall below the cutoff before EtG does, producing an EtG-only result near the end of the detection window.
Active infection: Certain bacterial organisms in the urinary tract can affect glucuronide readings; consider evaluating for UTI.
Analytical issue: If the pattern is isolated, consider requesting a repeat specimen to confirm.

Do not report an EtG-positive/EtS-negative result as confirmed alcohol consumption without additional context. A repeat UA is appropriate.

EtS is a highly specific marker for hepatic ethanol metabolism. Its absence alongside a positive EtG is the exception, not the rule. Treat this pattern as atypical and investigate before making a final determination. Reference: TP-ETG-V01

A positive urine ethanol immunoassay screen with both EtG and EtS negative is inconsistent with alcohol ingestion. This pattern is most consistent with in-cup fermentation: ethanol produced within the specimen after collection through bacterial or yeast activity. Unlike ingested ethanol, fermentation cannot generate EtG or EtS, because those metabolites are produced only through hepatic metabolism.

Three factors drive in-cup fermentation:

Glucosuria (uncontrolled diabetes): Glucose spills into the urine and acts as a fermentation substrate for bacteria or yeast.
Bacterial or yeast contamination in the collection cup.
Prolonged processing delay: The longer the specimen sits at ambient temperature before processing, the more fermentation can occur.

Note: the urine ethanol immunoassay screen has a detection window of approximately 2 to 12 hours and is insufficient on its own to confirm alcohol use.

When the ethanol screen is positive but EtG and EtS are both negative, the specimen is exculpatory, not confirmatory. Ask about diabetes history and confirm the specimen was processed without unusual delay. Reference: TP-ETG-V01

Possibly at low concentrations, but only under specific circumstances. Commercially regulated kombucha in the US must contain less than 0.5% ABV; home-brew or improperly stored kombucha can exceed 1 to 3% ABV due to continued fermentation from live cultures. If both EtG and EtS exceed cutoff, the ethanol load required to produce those levels is biologically equivalent to beverage alcohol consumption, regardless of source.

General framework for evaluating a fermented food defense:

EtG below 100 ng/mL: Dietary sources plausible; incidental exposure is possible.
EtG 100 to 500 ng/mL: Possible; evaluate specific sources and consumption volume in context.
EtG above 500 ng/mL: Dietary sources unlikely as the sole explanation; substantial cumulative intake would be required.
EtG above 1,000 ng/mL: Fermented food sources insufficient to reliably produce this level.

The source of the ethanol does not change the pharmacology. Whether the patient drank wine or consumed enough home-brew kombucha to reach an equivalent blood ethanol level, the hepatic metabolic result is the same. Evaluate the defense based on whether the claimed source and volume are physiologically sufficient to account for the measured EtG level. Reference: TP-ETG-V02

Yes. Dilution reduces the absolute concentrations of EtG and EtS proportionally but cannot generate them from non-alcohol sources. Both markers are produced only through hepatic metabolism of ingested ethanol; excess fluid intake cannot create them. A positive EtG/EtS result in a dilute specimen remains valid for determining alcohol use, provided the concentration still meets or exceeds the applicable cutoff threshold.

A pattern of recurrent dilute specimens with intermittent EtG/EtS positives is more consistent with ongoing alcohol use combined with intentional system flushing than with incidental exposure. Documenting this pattern is important for building the clinical narrative.

Dilution suppresses concentrations but cannot fabricate metabolites. A patient who is recurrently dilute but occasionally tests positive for both EtG and EtS is showing you two things simultaneously: continued alcohol use and an attempt to mask it. Reference: TP-ETG-V02

Yes, and the two markers are affected differently. EtG (a glucuronide) is vulnerable to bacterial beta-glucuronidase: in specimens with a UTI or significant bacteriuria, EtG can be completely hydrolyzed within hours at room temperature, producing a false-negative. If free ethanol is also present (from glucosuria or contamination), bacteria can synthesize EtG post-collection, producing a false-positive. EtS (a sulfate ester) is stable under every condition studied; no organism tested has degraded or synthesized it, making it the effective stability control.

EtG/EtS stability by specimen condition:

Condition	EtG Stability	EtS Stability
Room temp, no bacteria	Stable up to 3 weeks (Wurst 2006)	Stable
Room temp + bacteria (no ethanol)	UNSTABLE: complete hydrolysis within 24 h possible (Helander 2005)	Stable
Room temp + bacteria + ethanol	SYNTHESIZED: de novo EtG in 35% of negative specimens; up to 17.6 mg/L (Helander 2007)	No formation
Refrigerated (4-8°C)	Risk reduced but not eliminated (Thierauf 2008)	Stable
Frozen (-20°C)	Reliable; no bacterial growth	Stable

Discordant EtG/EtS patterns:

Pattern	Most Likely Mechanism	Recommended Action
EtG positive / EtS positive	Consistent with alcohol ingestion and hepatic metabolism	Document; supports determination of alcohol use
EtG negative / EtS positive	EtG hydrolysis by beta-glucuronidase; does not confirm abstinence when bacteriuria present	Evaluate UA for bacteriuria; do not report as confirmed negative; consider repeat specimen
EtG positive / EtS negative	Post-collection EtG synthesis from bacterial conjugation of free ethanol; glucosuria or prolonged warm transit	Check for glucosuria; review transit conditions; do not report as confirmed positive without EtS

Consultant's Pearl (TP-ETG-V03): The safest EtG interpretation always includes EtS. If only EtG is ordered and bacteriuria was present, the result is uninterpretable in either direction. Refrigeration reduces risk but does not eliminate it; freezing at -20°C is reliable for specimens that must be held. Preservative compatibility with the specific immunoassay in use should be verified: thymol accelerates EtG loss at room temperature; sodium azide has been validated for the DRI EtG immunoassay (Luginbuhl 2017).

"Were both EtG and EtS ordered, and what were the results for each? A single-marker EtG order limits the interpretation significantly."

[If EtG negative / EtS positive:]

"This pattern suggests EtG was destroyed by bacterial beta-glucuronidase. EtS is stable under all conditions studied. The positive EtS is consistent with prior alcohol metabolism. The negative EtG in a specimen with bacteriuria may reflect a handling artifact rather than abstinence. Does the patient have a UTI or was the UA positive for bacteriuria?"

[If EtG positive / EtS negative:]

"After drinking, both EtG and EtS should be present. An absent EtS raises concern for post-collection EtG synthesis, which can occur when bacteria are present along with free ethanol or glucose in the specimen. I would check for glucosuria and review specimen transit conditions before reporting this as a positive for alcohol use."

📋Other Clinical Topics

Patients taking venlafaxine (Effexor) will test positive for both venlafaxine and its active metabolite O-desmethylvenlafaxine (desvenlafaxine). Patients taking only desvenlafaxine (Pristiq) may or may not show venlafaxine depending on minor back-metabolism. The FDA recognizes desvenlafaxine as a distinct chemical entity from venlafaxine.

Creatinine is an endogenously produced byproduct of muscle metabolism, cleared by the kidneys at a relatively constant rate. Normal urine creatinine: at or above 20 mg/dL. Used to assess urine concentration, normalize drug results, and identify specimen validity issues. Abnormal creatinine may also result from renal disease, reduced renal blood flow, or high meat diet: not always indicative of tampering.

Most drugs are detectable in urine within 2–6 hours of oral ingestion. Onset is faster with IV or inhalation routes. If a patient claims to have taken their medication right before specimen collection, detection in urine would typically require at least 2 hours for the medication to be metabolized and excreted.

No. The DEA has issued a memorandum prohibiting clinical laboratories from accepting non-patient samples for drug concentration testing. Clinical labs are authorized to test patient specimens only.

No FAQ entries match your search. Try different keywords.

Clinical toxicology FAQ reference for drug test interpretation.